Other Information.
−Removed: None of the Company's directors and officers adopted, modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company's fiscal quarter ended March 31, 2026 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).
+Added: None of the Company's directors and officers adopted, modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company's fiscal quarter ended June 30, 2026 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).
EXHIBIT INDEX
+Added: Amendment No.
+Added: 5 to Edesa Biotech, Inc.
+Added: 2019 Equity Incentive Compensation Plan (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on May 29, 2026, and incorporated herein by reference).
+Added: Form of Purchase Agreement, dated June 10, 2026, by and among the Company and the Purchasers (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on June 11, 2026, and incorporated herein by reference).
+Added: Form of Registration Rights Agreement, dated June 10, 2026, by and among the Company and the Purchasers (included as Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed on June 11, 2026, and incorporated herein by reference).
Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
14 unchanged sentences
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
+Added: August 13, 2026
EDESA BIOTECH, INC.
/s/ Pardeep Nijhawan
−Removed: Pardeep Nijhawan, MD, Director, Chief Executive Officer and
−Removed: Corporate Secretary
+Added: Pardeep Nijhawan, MD, Director, Chief Executive Officer and Corporate Secretary
(Principal Executive Officer)
+Added: August 13, 2026
Weiler, Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.